8-K: Acurx Pharmaceuticals Secures $12 Million Stock Purchase Agreement with Lincoln Park Capital

Acurx Pharmaceuticals has entered into a purchase agreement with Lincoln Park Capital for up to $12 million in shares of common stock to fund working capital and general corporate purposes.

Summary

• Acurx Pharmaceuticals, Inc. has entered into a purchase agreement with Lincoln Park Capital Fund, LLC, for up to $12.0 million in shares of the company's common stock.
• The agreement allows Acurx, at its sole discretion, to sell shares to Lincoln Park over a 24-month period, commencing upon the effectiveness of a registration statement.
• Acurx will issue 899,258 shares of common stock to Lincoln Park as consideration for its commitment.
• The company intends to use the proceeds from these sales for working capital and general corporate purposes.
• Sales of common stock to Lincoln Park will depend on market conditions, the trading price of Acurx's common stock, and the company's funding needs.
• The purchase price per share for each Regular Purchase will be 97% of the lower of (i) the lowest sale price of our common stock on the business day on which we initiate the Regular Purchase and (ii) the average of the three lowest closing sale prices of our common stock during the 10-business day period immediately preceding the business day on which we initiate the Regular Purchase.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The agreement provides Acurx with access to capital, but there are potential risks associated with dilution and market conditions.

Positives

• Acurx gains access to up to $12.0 million in funding over a 24-month period.
• The agreement provides flexibility for Acurx to draw capital as needed, based on market conditions and the company's funding requirements.
• The company retains the right to terminate the Purchase Agreement at any time after the Commencement Date, at no cost or penalty.

Negatives

• The company is limited by Nasdaq rules and may not issue or sell to Lincoln Park more than 19.99% of the shares of common stock outstanding immediately prior to the execution of the Purchase Agreement, unless stockholder approval is obtained or the average price of all applicable sales equals or exceeds $0.3545 per share.
• The company may face dilution of existing shareholders' equity if it sells a significant number of shares to Lincoln Park.
• The purchase price is set at 97% of the lower of the lowest sale price on the purchase day or the average of the three lowest closing sale prices during the preceding 10 business days, which may be lower than the current market price.

Risks

• Sales of shares to Lincoln Park will depend on market conditions and the trading price of Acurx's common stock, which are subject to change.
• The company's ability to access the full $12.0 million is contingent on satisfying certain conditions and limitations outlined in the Purchase Agreement.
• The company's stock price could be negatively impacted by the issuance of new shares, potentially leading to dilution for existing shareholders.
• The company's reliance on this funding source could be a risk if Lincoln Park is unable or unwilling to purchase shares as directed.

Future Outlook

The company expects that any proceeds received from sales of common stock to Lincoln Park will be used for working capital and general corporate purposes.

Management Comments

• The company intends to use the proceeds from these sales for working capital and general corporate purposes.

Industry Context

This type of financing agreement is common for small-cap and micro-cap companies seeking to raise capital. These agreements provide flexibility but can also lead to stock dilution.

Comparison to Industry Standards

• Similar agreements are often used by companies like Acurx with limited access to traditional financing.
• Comparable companies that have used similar financing structures include those in the biotechnology and pharmaceutical sectors with ongoing research and development needs.
• The terms of the agreement, such as the discount on the purchase price (3%), are within the typical range for these types of transactions.

Stakeholder Impact

• Shareholders may experience dilution if Acurx sells a significant number of shares to Lincoln Park.
• The company's employees and operations will benefit from the additional working capital.
• The company's creditors may view the agreement positively as it strengthens Acurx's financial position.

Next Steps

• Acurx must file a registration statement with the SEC covering the resale of the shares.
• The company needs to satisfy the conditions outlined in the Purchase Agreement to commence sales of shares to Lincoln Park.
• Acurx may need to obtain stockholder approval to issue shares in excess of the Exchange Cap, depending on the average price of sales to Lincoln Park.

Key Dates

Keywords

Acurx Pharmaceuticals, Lincoln Park Capital, stock purchase agreement, common stock, funding, capital raise, securities, registration rights, Nasdaq, dilution